Increased protein O-GlcNAc modification inhibits inflammatory and neointimal responses to acute endoluminal arterial injury

Am J Physiol Heart Circ Physiol. 2008 Jul;295(1):H335-42. doi: 10.1152/ajpheart.01259.2007. Epub 2008 May 9.

Abstract

Inflammation plays a major role in vascular disease. We have shown that leukocyte infiltration and inflammatory mediator expression contribute to vascular remodeling after endoluminal injury. This study tested whether increasing protein O-linked-N-acetylglucosamine (O-GlcNAc) levels with glucosamine (GlcN) and O-(2-acetamido-2-deoxy-d-glucopyranosylidene) amino-N-phenylcarbamate (PUGNAc) inhibits acute inflammatory and neointimal responses to endoluminal arterial injury. Ovariectomized rats were treated with a single injection of GlcN (0.3 mg/g ip), PUGNAc (7 nmol/g ip) or vehicle (V) 2 h before balloon injury of the right carotid artery. O-GlcNAc-modified protein levels decreased markedly in injured arteries of V-treated rats at 30 min, 2 h, and 24 h after injury but returned to control (contralateral uninjured) levels after 14 days. Both GlcN and PUGNAc increased O-GlcNAc-modified protein levels in injured arteries compared with V controls at 30 min postinjury; the GlcN-mediated increase persisted at 24 h but was not evident at 14 days. Proinflammatory mediator expression increased markedly after injury and was reduced significantly (30-50%) by GlcN and PUGNAc. GlcN and PUGNAc also inhibited infiltration of neutrophils and monocytes in injured arteries. Chronic (14 days) treatment with GlcN reduced neointima formation in injured arteries by 50% compared with V controls. Acute GlcN and PUGNAc treatment increases O-GlcNAc-modified protein levels and inhibits acute inflammatory responses in balloon-injured rat carotid arteries; 14 day GlcN treatment inhibits neointima formation in these vessels. Augmenting O-GlcNAc modification of proteins in the vasculature may represent a novel anti-inflammatory and vasoprotective mechanism.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylglucosamine / analogs & derivatives*
  • Acetylglucosamine / pharmacology
  • Animals
  • Anti-Inflammatory Agents / pharmacology*
  • Carotid Arteries / drug effects*
  • Carotid Arteries / metabolism
  • Carotid Arteries / pathology
  • Carotid Artery Injuries / drug therapy*
  • Carotid Artery Injuries / metabolism
  • Carotid Artery Injuries / pathology
  • Disease Models, Animal
  • Female
  • Glucosamine / pharmacology*
  • Glycosylation
  • Inflammation Mediators / metabolism*
  • Monocytes / drug effects
  • Monocytes / metabolism
  • Neutrophil Infiltration / drug effects
  • Ovariectomy
  • Oximes / pharmacology*
  • Phenylcarbamates / pharmacology*
  • Protein Processing, Post-Translational / drug effects*
  • Rats
  • Rats, Sprague-Dawley
  • Time Factors

Substances

  • Anti-Inflammatory Agents
  • Inflammation Mediators
  • Oximes
  • Phenylcarbamates
  • N-acetylglucosaminono-1,5-lactone O-(phenylcarbamoyl)oxime
  • Glucosamine
  • Acetylglucosamine